pSivida Limited Announcement: DSMB Supports Continuation of the Phase III Clinical Trial of Iluvien(TM) for the Treatment of DME
Published: Sep 25, 2008
BOSTON--(BUSINESS WIRE)--Global drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3) today announced that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has once again recommended that the two pivotal Phase III clinical trials, known collectively as the FAME™ (Fluocinolone Acetonide in Diabetic Macular Edema) Study continue under the current protocol, without change. The trial is studying the use of MedidurTM FA for the treatment of diabetic macular edema (DME) being conducted by our licensing partner, Alimera Sciences. MedidurTM FA will be marketed under the name IluvienTM.